Draig Therapeutics emerges with $140M

Editor's Pick

Top Story Draig Therapeutics Emerges With $140M for Clinical Tests of Novel Neuropsychiatric Drugs Draig Therapeutics' lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is associated with mood disorders. The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing. Sponsored Driving Healthcare Innovation Across Payers, Providers & Life Sciences Presented by Veradigm 88% of providers agree: smoother payer interactions are essential. Veradigm helps bridge the gap between health plans and providers to reduce friction and improve outcomes. Join the network built to support collaboration and real-world success. See how we can help — Click to Learn More.

Featured News

Bluebird Kids Health to Expand By Opening New Pediatric Clinics Just a year after its launch, Bluebird Kids Health is already announcing plans to double its number of pediatric clinics. The startup seeks to improve pediatric care access in underserved areas by building practices in these neighborhoods and accepting all insurance types. Sword Health Raises $40M, Launches Mental Health Solution Sword Health's $40 million funding round was led by General Catalyst. In total, the company has raised $300 million. The most recent round brings its valuation to $4 billion. How Emerging Hospital Bed Technology Can Help Patients Rest Easier And Recover Faster Despite their necessity, beds and surfaces do not always receive proportional attention and innovation — even as the risks associated with prolonged bed rest remain a key priority for caregivers. AI Governance: Building Trust and Transparency for Healthcare AI Those who recognize that AI governance is an innovation enabler will be able to align business priorities and AI investments — and make smarter decisions about which models to accelerate, and which to retire — ultimately leaving the enterprises better positioned to achieve ROI on their AI.

Video   Why Should Employers Be Focused on HIV? At AHIP 2025, Tracy Watts of Mercer discussed why employers should be paying more attention to HIV. "You might be surprised to know that the fastest growing test-positive cohort for HIV is ages 25 to 34 — these are your workers that weren't even alive at the beginning of the AIDS epidemic. Related to that, 80% of the people who transmit HIV don't even know that they have it," she said. In her view, the best thing employers can do to help address this issue is to promote HIV testing.

Sponsored 5 Companies That Offer Mobile IV Therapy With Experienced Nurses in NYC and Beyond Presented by IV Elements Get your IV treatment from wherever you are. These top companies provide mobile IV therapy administered by experienced nurses in NYC and beyond. Learn More

Resources

MedCity Pivot: How Veradigm Aims to Close the Information Gap Megan Zakrewsky, vice president of product at Veradigm talks about how the company is utilizing tech among providers, payers and patients. Watch now!

MedCity News • PO Box 901 • New York, NY unsubscribe